QL1706 plus chemo before surgery for esophageal cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests adding an immunotherapy drug (QL1706) to standard chemotherapy before surgery for a certain type of esophageal cancer. The goal is to see if the combination works better than chemotherapy alone at shrinking the tumor and improving surgery outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with squamous cell cancer of the esophagus that is locally advanced but can still be surgically removed.
- You have not had any prior treatment for this cancer.
- You are in good physical condition (able to care for yourself and do light activities).
- Your doctor expects to be able to remove all visible cancer during surgery after the initial treatment.
- You do not have major bleeding issues, significant tumor invasion into nearby organs, or uncontrolled fluid buildup in your body.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug, QL1706, given before surgery for esophageal squamous cell cancer. The goal is to see if it helps shrink tumors and improve outcomes for patients who are healthy enough for the treatment.
This study tests a new treatment approach for patients with advanced esophageal cancer whose disease progressed or didn't respond to initial chemotherapy and immunotherapy. The goal is to see if this new treatment can help shrink tumors and improve outcomes for patients who cannot have surgery.
This trial tests whether adding a new drug called QL1706 to standard chemotherapy (two common cancer drugs) works better for advanced esophageal cancer that can't be surgically removed. The goal is to see if this combination helps patients live longer and controls the cancer better than chemotherapy alone.
This trial tests a combination of two immunotherapy drugs, chemotherapy, and lenvatinib before surgery to treat esophageal squamous cell carcinoma that hasn't spread and can be removed. It aims to see if this approach can improve outcomes for patients with stage II to IVa disease.
This trial tests a new drug called QL1706 combined with standard chemotherapy to see if it can shrink esophageal tumors that are hard to remove with surgery alone. It’s for people who haven’t had any treatment yet and are well enough for daily activities.
This trial tests whether adding a new immunotherapy drug called QL1706 to standard chemotherapy before surgery can help treat early-stage cervical cancer better. The goal is to shrink tumors and improve outcomes for patients who haven't had immune therapy before.
Hear when a new Resectable Locally Advanced Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.